CRISPR THERAPEUTICS AG (CRSP)
Health Care · Biotechnology · NASDAQ
CRISPR Therapeutics is a biopharmaceutical company pioneering gene-editing therapies to treat and potentially cure severe genetic diseases using its proprietary CRISPR/Cas9 technology.
What CRISPR THERAPEUTICS AG does
CRISPR Therapeutics is a gene editing company focused on developing transformative gene-based medicines for serious human diseases. Utilizing its proprietary CRISPR/Cas9 platform, the company is advancing a diversified pipeline of product candidates for hemoglobinopathies, oncology, regenerative medicine, and rare diseases.
Themes: gene editing, CRISPR/Cas9 technology, genetic disease therapy, cell therapy, immunotherapy, biotechnology
Fundamentals
- Price$49.88 as of 2026-10-20 close
- Market cap$4.8B as of 2026-07-31 (share count; price 2026-10-20)
- 1-year return-32.6% 2025-10-20 close $73.97 → 2026-10-20 close $49.88
- P/En/a negative earnings
- Net margin-16569.8% FY2025, SEC XBRL
- ROE-30.3% FY2025, SEC XBRL
- ROICn/a No figure: its pre-tax income was zero or negative, so there is no tax rate to apply.
- Debt / equity0.34 borrowings, leases excluded / equity — 10-Q/10-K balance sheet 2026-06-30
- Revenue growth (YoY)-90.6% FY2025, SEC XBRL
- Revenue CAGR (3y)+43.1% SEC XBRL
- Beta1.43 as of 2026-09-03
- Last reported earnings2026-08-03 SEC EDGAR Form 8-K (Item 2.02)
How CRSP compares in its sector
- net profit marginbottom 10% 430 covered Health Care peers, as of 2026-09-03
- operating marginbottom 10% 417 covered Health Care peers, as of 2026-09-03
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRtop 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 10% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
CRSP is not currently in any published Top 10 list. Its scores are below.
Top 10 score
32.0 #1206 of 1,265 scored · #140 of 146 in Health Care
Valuation 59th (price to book 2.8) and growth 48th (3-year revenue CAGR 43.1%, revenue growth year over year -90.6%); weakest is profitability (3rd, operating margin -18933.6%, return on equity -30.3%).
Scores as of 20 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4.
Quarterly results
| Quarter | Revenue | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | $10M | -$117M | -$91M | -$0.94 | -$83M† | $648000† |
| Q1 FY2026 2026-03-31 | $1M | -$130M | -$123M | -$1.28 | -$109M | $504000 |
| Q4 FY2025 2025-12-31 | $864000† | -$155M† | -$131M† | -$1.35† | -$93M† | $517000† |
| Q3 FY2025 2025-09-30 | $889000 | -$132M | -$106M | -$1.17 | -$85M† | $74000† |
| Q2 FY2025 2025-06-30 | $892000 | -$229M | -$209M | -$2.40 | -$114M† | $117000† |
| Q1 FY2025 2025-03-31 | $865000 | -$148M | -$136M | -$1.58 | -$54M | $206000 |
| Q4 FY2024 2024-12-31 | $36M† | -$65M† | -$37M† | -$0.42† | -$50M† | $254000† |
| Q3 FY2024 2024-09-30 | $602000 | -$110M | -$86M | -$1.01 | -$107M† | $219000† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$291M
- Short-term investments$2.1B
- Total debt$586M borrowings only; leases excluded
- Net debt-$1.8B total debt − cash − short-term investments
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How CRISPR THERAPEUTICS AG looks technically
CRISPR THERAPEUTICS AG (CRSP) is trading 6.0% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed above its 200-day average about 20 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 13, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 41, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 3 trading days ago. It is 33.5% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 6.0% below its 200-day average, the long-term trend line — a long-term downtrend | -6.0% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $54.80 | $54.80 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $53.09 | $53.09 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 14 calendar days ago — the swings before that are what the structure reading is measured on | 14 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 60.68. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 20 trading days ago — a "golden cross", a bullish long-term signal | 20 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 13, below the 25 that marks a real trend) | 13.2 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 41, neither overbought (above 70) nor oversold (below 30) | 41.3 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($47.36 to $60.68) — its "stochastic" reading is 19 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 18.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 11 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $75.06 | $75.06 |
|---|---|---|
| From the 52-week high | it is 33.5% below its 52-week high (its highest price of the past year) | -33.5% |
| Above the 52-week low | it is 13.1% above its 52-week low (its lowest price of the past year) | +13.1% |
| Below the 52-week high | it is 33.5% below its highest point of the past year | 33.5% |
| Since a 20-day breakout | it made a new 20-day low about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it is trading within its recent 55-day range, with no fresh breakout up or down | 0 sessions |
| All-time high | its highest closing price on record is $220.20 (set on 2021-01-15) | $220.20 |
| Given back of the 52-week move | over the past year its closes ranged ($44.34 to $73.97), and it has recovered roughly a quarter of its fall from last year’s high — 19% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $62.65 to $63.60. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 18.7% |
| From the all-time high | it is 77.3% below its all-time high | -77.3% |
| Nearest price level | it is trading 1.6% above a support level at $49.06 — a price it turned at three times since 2026-04-24, most recently on 2026-06-11. Since 2024-10-21 it has 5 such levels below the current price and 6 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -1.6% |
| All-time low | its lowest closing price on record is $11.63 (set on 2017-02-15) | $11.63 |
| Above the all-time low | it is 328.9% above its all-time low | +328.9% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 41st percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $2.73 between its high and its low — about 5.5% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $2.73 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $48.13 and $58.07 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $48.13 – $53.10 – $58.07 |
| Typical daily range (% of price) | its price moves about 5.5% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.5% |
| Stretch from the 200-day average | it is trading 1.2 daily ranges below its 200-day average price (6.0% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.2 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.29× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 0.1% since the prior reading | -0.1% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Price gaps
2
| Gap at the open | it opened on 2026-10-20 2.3% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -2.3% |
|---|---|---|
| Gap filled | a 2.3% gap down opened on 2026-10-20 has been "filled" today — price traded back through the level the gap left behind, and it closed again during the very session that opened it | today |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 12.8 percentage points (the stock lost 11.8% while the market gained 1.0%) | -12.8% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 2.5 percentage points (the stock gained 6.2% while the market gained 3.6%) | +2.5% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 22.1 percentage points (the stock lost 13.5% while the market gained 8.5%) | -22.1% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 47.1 percentage points (the stock lost 32.6% while the market gained 14.6%) | -47.1% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bearish state: trading below its 200-day average, a fresh 20-day low, MACD momentum is negative, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 8.8% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 2.8% of the share price. | -8.8% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 6% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $53.18 — a volume-weighted average of daily closes over 198 sessions, not a true tick-by-tick VWAP. | -6.2% |
|---|---|---|
| Vs the average paid since it last reported | the price is 9% below the average price paid since it last reported on 2026-08-03 (its 10-Q), so the typical buyer over that stretch is under water. That average is $54.83 — a volume-weighted average of daily closes over 56 sessions, not a true tick-by-tick VWAP. | -9.0% |
Inverse head and shoulders, bullish — forming · entry $59.83 · 89 sessions in
Symmetrical triangle, either side — broke down · the lower entry $54.31 · 75 sessions in
Price levels it has turned at before
CRSP last closed at $49.88 on 2026-10-20. Since 2024-10-21 it has turned at 5 prices below its last close and 6 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $49.06 | Support | 1.6% below the last close | turned there three times · 2026-04-24 to 2026-06-11 |
| $51.50 | Resistance | 3.2% above the last close | turned there 7 times · 2025-08-20 to 2026-09-14 |
| $52.70 | Resistance | 5.7% above the last close | turned there twice · 2025-08-05 to 2026-09-28 |
| $45.75 | Support | 8.3% below the last close | turned there five times · 2024-11-21 to 2026-07-28 |
| $44.20 | Support | 11.4% below the last close | turned there twice · 2025-01-06 to 2026-03-30 |
| $55.70 | Resistance | 11.7% above the last close | turned there four times · 2024-12-02 to 2026-05-11 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $60.68.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 6 trading days, since 2026-10-13.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Trading below the 50-day moving average · Recent golden cross (50-day crossed above 200-day) · Pulled back from the 12-month high · Broke down to a new 20-day low · trendless / choppy (low ADX) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (2.05 mean, 1=Strong Buy…5=Strong Sell) — 18 analysts
- Mean price target$87.50 range $44.00 – $291.00; median $80.00
Analyst estimates, as of 2026-10-15. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for CRSP
- Consensus EPS estimate-$1.08 next reporting period, as of 2026-10-15
- Estimate change, 30 days-$0.03004 from -$1.05, on 2026-09-10, 35-day window
- Readings revised upward0% of 7 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Significant history of operating losses and uncertainty regarding future profitability","Heavy reliance on collaboration and license agreements with strategic partners","Intense competition in the gene editing and biopharmaceutical sectors"]
What changed in the latest 10-Q
AI-assisted comparison of CRSP's 10-Q filed 2026-08-03 against the prior one filed 2026-05-04.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-08-03) adds the sentence: "Additionally, in July 2026, the FDA approved expanded use of CASGEVY in the United States for the treatment of eligible patients ages 2 years and older with either SCD or TDT. CASGEVY is the first approved genetic therapy indicated for children as young as 2 years for both SCD and TDT."
- Newer filing (2026-08-03) adds that CASGEVY has been approved "in certain countries in the Middle East, including the Kingdom of Saudi Arabia" (older filing only said "certain countries in the Middle East").
- Newer filing (2026-08-03) adds statements that Phase 1 clinical trials have been initiated for CTX340 (directed towards angiotensinogen, for refractory hypertension) and CTX460 (directed towards SERPINA1 using SyNTase, for alpha-1 antitrypsin deficiency).
- Removed:
- Older filing (2026-05-04) stated that CTX340, CTX321 and CTX460 are currently in IND/CTA-enabling studies; this status statement is removed in the newer filing (2026-08-03), which instead describes CTX340 and CTX460 Phase 1 trial initiation and states only CTX321 is currently in IND/CTA-enabling studies.
- Reworded:
- Older filing (2026-05-04) grouped CTX340, CTX321 and CTX460 together as earlier stage programs in IND/CTA-enabling studies; newer filing (2026-08-03) separates them, states CTX340 and CTX460 have initiated Phase 1 clinical trials, and states only CTX321 is currently in IND/CTA-enabling studies.
- Notes:
- The provided newer text is truncated after the first paragraph of the siRNA-based Programs subsection; only content shown in both excerpts was compared.
- The older text excerpt ends mid-page with a page break indicator ("19") and the newer text excerpt ends mid-section, so changes beyond the visible portions cannot be assessed.
Risk Factors
- Added:
- In the newer filing (filed 2026-08-03), the Risk Factors section states there have been no material changes to the risk factors previously disclosed in the Annual Report on Form 10-K (filed February 12, 2026) and the Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 (filed May 4, 2026).
- In the newer filing (filed 2026-08-03), Item 5(c) includes a table disclosing that James R. Kasinger (General Counsel and Secretary) adopted a Rule 10b5-1 trading plan on May 6, 2026 for sale of common stock, active through May 31, 2027, covering 93,632 securities.
- In the newer filing (filed 2026-08-03), Item 5(c) includes a table disclosing that Raju Prasad, Ph.D. (Chief Financial Officer) adopted a Rule 10b5-1 trading plan on June 9, 2026 for sale of common stock, active through May 31, 2027, covering 14,565 securities.
- In the newer filing (filed 2026-08-03), the Exhibit Index lists new Exhibits 10.1 through 10.7 related to the CRISPR Therapeutics AG 2026 Stock Option And Incentive Plan and related award agreement forms, each incorporated by reference to a Form 8-K filed on June 4, 2026.
- Removed:
- In the older filing (filed 2026-05-04), the Risk Factors section includes a risk factor titled 'Our Indebtedness and Liabilities Could Limit the Cash Flow Available for Our Operations, Expose Us to Risks That Could Adversely Affect Our Business, Financial Condition and Results of Operations and Impair Our Ability to Satisfy Our Obligations Under the Notes,' which is not present in the newer filing.
- In the older filing (filed 2026-05-04), the Risk Factors section includes a risk factor titled 'Transactions Relating To Our Notes May Affect The Value Of Our Common Shares,' which is not present in the newer filing.
- In the older filing (filed 2026-05-04), Item 5(c) states that during the three months ended March 31, 2026, none of the officers and directors adopted, modified or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement. This statement is not present in the newer filing.
- In the older filing (filed 2026-05-04), the Exhibit Index lists Exhibits 4.1 and 4.2 related to the Indenture dated March 16, 2026 and the Form of Global Note for Convertible Senior Notes due 2031, which are not present in the newer filing.
- Reworded:
- In the older filing (filed 2026-05-04), the Risk Factors section states it is 'updating and supplementing' risk factors to add the new note-related risk factors; in the newer filing (filed 2026-08-03), this wording is replaced by a statement that there have been no material changes to the previously disclosed risk factors.
- In the older filing (filed 2026-05-04), Item 5(c) describes the period as 'the three months ended March 31, 2026'; in the newer filing (filed 2026-08-03), Item 5(c) describes the period as 'the three months ended June 30, 2026'.
- Notes:
- The provided texts include content beyond the Risk Factors section (Items 2 through 6 and signatures); all changes within those items are reported because they were included in the supplied section texts.
- The comparison relies solely on the two supplied excerpt texts and does not verify the full SEC filings.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 7 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-16. The 5 days since 2026-10-16 have not been checked yet.
- Last 30 days · read to 2026-10-160 buys · 6 sells ($4M) — 3 selling insiders
- Last 90 days · read to 2026-10-160 buys · 7 sells ($5M) — 4 selling insiders
- Last 180 days · read to 2026-10-160 buys · 8 sells ($5M) — 5 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-10-19. Based on Form 4 filings read through 2026-10-16; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about CRSP's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Short interest (FINRA)
CRSP had 18,679,198 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
CRSP had 19.3% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 9.58 days to cover at the same settlement.
- Reported short interest (shares) 18,679,198
- Short interest (% of shares outstanding) 19.3%
- Prior settlement (shares) 19,071,093
- Reported change -2.05%
- Days to cover (reported) 9.58
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Vertex Pharmaceuticals (VRTX)
- Intellia Therapeutics (NTLA)
- Editas Medicine (EDIT)
- Bluebird Bio (BLUE)
- Beam Therapeutics (BEAM)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare CRSP vs…
CRISPR THERAPEUTICS AG is found in…
Frequently asked questions
What does CRISPR THERAPEUTICS AG (CRSP) do?
CRISPR Therapeutics is a gene editing company focused on developing transformative gene-based medicines for serious human diseases. Utilizing its proprietary CRISPR/Cas9 platform, the company is advancing a diversified pipeline of product candidates for hemoglobinopathies, oncology, regenerative medicine, and rare diseases.
What sector is CRISPR THERAPEUTICS AG (CRSP) in?
CRISPR THERAPEUTICS AG (CRSP) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Who are CRISPR THERAPEUTICS AG's (CRSP) competitors?
Notable peers of CRISPR THERAPEUTICS AG (CRSP) include Vertex Pharmaceuticals, Intellia Therapeutics, Editas Medicine, Bluebird Bio and Beam Therapeutics. This peer set is informational only — not financial advice.
Is CRISPR THERAPEUTICS AG (CRSP) overbought or oversold right now?
CRISPR THERAPEUTICS AG (CRSP) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 41, in the neutral middle (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on CRSP come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.